Casdin Capital’s Maze Therapeutics MAZE Stock Holding History
Bought
Maintained
Sold
Other funds holding MAZE
Casdin Capital's MAZE Position: Q3 2026 in Review
Casdin Capital held its Maze Therapeutics (MAZE) position steady in Q3 2026 at 843,857 shares worth $22.9M. The position accounts for 1% of the portfolio, ranked #20.
Casdin Capital first reported a position in MAZE in Q1 2025 and has held it in 7 quarters since. The position peaked at $31.4M in Q4 2025. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.
- Casdin Capital held 843,857 shares of Maze Therapeutics worth $22.9M as of Q3 2026.
- Casdin Capital left its Maze Therapeutics share count unchanged in Q3 2026.
- Maze Therapeutics made up 1% of Casdin Capital's portfolio in Q3 2026, its #20 holding.
- Casdin Capital first reported a position in Maze Therapeutics in Q1 2025 and has held it in 7 quarters since.
- Casdin Capital's Maze Therapeutics position peaked at $31.4M in Q4 2025.
- 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.
Based on Casdin Capital's 13F filing for Q3 2026, filed 16 Nov 2026.